{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:29:45Z","timestamp":1787840985973,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Species-specific antimicrobial susceptibility testing is crucial for the effective treatment of nontuberculous mycobacteria (NTM). In this study, the\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      antimicrobial activities of two next-generation antibacterial agents, tedizolid (TZD) and omadacycline (OMC) \u2013 which have demonstrated strong\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      activity against NTM species but have not been comprehensively evaluated for NTM treatment in Turkiye \u2013 were investigated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this study, antibiotic susceptibility testing for TZD and OMC was performed on a total of 104 NTM isolates (59 rapid-growing and 45 slow-growing) using the colorimetric microdilution method, in accordance with Clinical and Laboratory Standards Institute (CLSI) M24 and M62 standards. Minimum inhibitory concentration (MIC) ranges were 0.015\u201332 \u00b5g\/ml for TZD and 0.003\u201364 \u00b5g\/ml for OMC. For the interpretation of TZD susceptibility, the CLSI M62 breakpoints established for linezolid were used (\u22648 \u00b5g\/ml: susceptible, 16 \u00b5g\/ml: intermediate, and \u226532 \u00b5g\/ml: resistant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the rapidly growing NTM isolates, only one\n                      <jats:italic toggle=\"yes\">Mycobacterium fortuitum<\/jats:italic>\n                      isolate was found to be intermediate (1\/29; 16 \u00b5g\/mL), while one\n                      <jats:italic toggle=\"yes\">Mycobacterium avium<\/jats:italic>\n                      isolate among the slowly growing species was classified as resistant (1\/6; \u226532 \u00b5g\/mL). The remaining 102 isolates were all found to be susceptible to TZD (\u22648 \u00b5g\/mL). Since no standardized breakpoint has yet been established for OMC, only the observed MIC values were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The findings demonstrated that TZD exhibits strong\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      activity against NTM isolates, whereas OMC showed a variable activity profile, particularly among rapidly growing species. These results support the necessity of basing antibiotic selection for the treatment of NTM infections on species-specific susceptibility testing.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_25_26","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:00:12Z","timestamp":1774641612000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of In vitro Efficacy of New Generation Drugs Tedizolid and Omadacycline against Nontuberculous Mycobacteria"],"prefix":"10.4103","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7815-1789","authenticated-orcid":false,"given":"Seda T\u00fcrkkal","family":"Arli","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli Ece","family":"\u00d6z\u00e7atalkaya","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"\u00c7ift\u00e7i","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, Istanbul Nisantasi University, Istanbul, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eafak Ceren","family":"U\u00e7ak","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Dentistry, Istanbul Kent University, Istanbul, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6rkem","family":"Yaman","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, Izmir Bakircay University, Izmir, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Satana","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"R1-20260416","first-page":"1","article-title":"Nontuberculous mycobacterial resistance to antibiotics and disinfectants: Challenges still ahead","volume":"8168750","author":"Tarashi","year":"2022","journal-title":"Biomed Res Int 2022"},{"key":"R2-20260416","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","article-title":"Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease","volume":"24","author":"Pennington","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R6-20260416","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-021-01000-6","article-title":"Therapeutic drug monitoring in non-tuberculosis mycobacteria infections","volume":"60","author":"Alffenaar","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R7-20260416","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jgar.2022.07.012","article-title":"Comparative study of in vitro activity of tedizolid and linezolid against Mycobacterium avium complex","volume":"30","author":"Marfil","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"R8-20260416","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijid.2021.06.055","article-title":"Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China","volume":"109","author":"Wen","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R9-20260416","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkz511","article-title":"Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?","volume":"75","author":"Ruth","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R10-20260416","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"Am Soc Microbiol J Clin Microbiol"},{"key":"R11-20260416","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40121-022-00750-5","article-title":"Contemporary pharmacotherapies for nontuberculosis mycobacterial infections: A narrative review","volume":"12","author":"Johnson","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R12-20260416","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fmicb.2020.00081","article-title":"Rational choice of antibiotics and media for Mycobacterium avium complex drug susceptibility testing","volume":"11","author":"Jaffr\u00e9","year":"2020","journal-title":"Front Microbiol"},{"key":"R13-20260416","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12866-022-02582-2","article-title":"In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Microbiol"},{"key":"R14-20260416","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.2147\/IDR.S362583","article-title":"In vitro susceptibility of nontuberculous mycobacteria to tedizolid","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"2000535","key":"R15-20260416","first-page":"1","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"R16-20260416","doi-asserted-by":"crossref","first-page":"250038","DOI":"10.1183\/16000617.0038-2025","article-title":"A systematic review of tetracyclines for nontuberculous mycobacteria: Focus on rapidly growing mycobacteria","volume":"34","author":"Daley","year":"2025","journal-title":"Eur Respir Rev"},{"key":"R17-20260416","doi-asserted-by":"crossref","first-page":"ofac028","DOI":"10.1093\/ofid\/ofac028","article-title":"Real-world use of tedizolid phosphate for 28 days or more: A case series describing tolerability and clinical success","volume":"9","author":"Morrisette","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R18-20260416","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","article-title":"Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"R19-20260416","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: A novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"R20-20260416","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciz242","article-title":"Omadacycline: A novel tetracycline derivative with oral and intravenous formulations","volume":"69","author":"Watkins","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R21-20260416","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R22-20260416","doi-asserted-by":"crossref","first-page":"e01947","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20260416","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R24-20260416","doi-asserted-by":"crossref","first-page":"e02522","DOI":"10.1128\/AAC.02522-18","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20260416","doi-asserted-by":"crossref","first-page":"e00470","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_25_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:38:52Z","timestamp":1787837932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_25_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_25_26","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-01-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}